GSK Plc
GlaxoSmithKline plc creates, discovers, develops, manufactures, and markets pharmaceutical products, including vaccines, over-the-counter medicines, and health-related consumer products worldwide. The company offers pharmaceutical products in the therapeutic areas, including respiratory, anti-virals, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterials, and emesis, dermatology, rare diseases, immuno-inflammation, vaccines, and HIV. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health areas. The companys wellness products include Panadol and Panadol Cold & Flu for headache, joint pain, fever, and cold symptoms; ENO and Tums that are immediate relief antacids; and Nicorette (US), Nicoderm, NiQuitin CQ, and Nicabate for the treatment of nicotine withdrawal as an aid to smoking reduction and cessation. Its oral health products comprise Sensodyne to treat and prevent dental sensitivity and acid erosion; Polident, Poligrip, and Corega to enhance comfort of fitted dentures and to clean dentures; and Aquafresh for the prevention of caries, gum disease, and bad breath. The companys nutrition products include Horlicks, a nutritional beverages and food; and skin health products comprise Physiogel, a face and body care product for dry, sensitive, and irritated skin, as well as Zovirax and Abreva to treat and prevent the onset of cold sores. GlaxoSmithKline plc was founded in 1935 and is headquartered in Brentford, the United Kingdom.
Trading 32% above its estimated fair value of $34.50.
Current Price
$50.90
-1.38%GoodMoat Value
$34.50
32.2% overvaluedGSK Plc (GSK) Financial Statements
GSK Computed Insights
Income Statement
Balance Sheet
Cash Flow Statement
GSK Financial Statements & Data
GSK Plc (GSK) financial data including income statement, balance sheet, and cash flow statement. This page provides a comprehensive view of GSK Plc's financial performance and position as a Healthcare company.
Trailing twelve-month (TTM) revenue is $44.31B. Gross profit (TTM) is $32.20B. EBITDA is $9.81B. Earnings per share (EPS) is $3.75. The P/E ratio is 13.09. Market capitalization is $103.72B.
Free cash flow (FCF) is $8.67B. FCF growth rate is -0.64%. EPS growth CAGR is 3.98%. Weighted average cost of capital (WACC) is 10.00%.
Historical revenue data covers 7 years from FY19 to FY25. Net income history spans 7 years. Free cash flow and capital expenditure data spans 7 years. GoodMoat displays interactive charts for revenue, net income, FCF vs CAPEX, and cash-to-debt ratios to help investors identify financial trends.
Use GSK Plc's financial data to assess the company's earnings quality, balance sheet health, and cash generation. Compare key metrics across periods to identify trends before making investment decisions with GoodMoat's valuation tools.